Literature DB >> 10446950

The relationship of untreated borderline infiltrates by the Banff criteria to acute rejection in renal allograft biopsies.

S M Meehan1, C T Siegel, A J Aronson, S M Bartosh, J R Thistlethwaite, E S Woodle, M Haas.   

Abstract

The relationship of borderline infiltrates to acute rejection by Banff criteria in renal allografts of patients receiving only maintenance immunosuppression is not clear. Renal allograft biopsies with borderline lesions that were not treated with additional anti-rejection therapy were retrospectively studied. Sixty-five such biopsies were identified from 50 patients, and their outcome was determined by serum creatinine and/or histologic findings in subsequent biopsies, up to 40 d after the initial biopsy. In addition to the borderline infiltrates, there was evidence of acute cyclosporine or tacrolimus toxicity (58%), acute tubular necrosis (12%), and urinary obstruction (12%). Forty-day follow-up after 30 (46%) biopsies revealed serum creatinine < 110% of baseline, and repeat biopsies were not indicated. In 17 (26%), the serum creatinine initially decreased, then increased, and follow-up biopsies showed acute rejection in nine. In 18 (28%), the creatinine remained elevated and follow-up biopsies revealed acute rejection in nine. The untreated borderline infiltrates were thus nonprogressive after 47 biopsies (72%) and progressed to histologic acute rejection after 18 (28%). When there was increasing or persistently elevated creatinine after the initial biopsy, 51% of cases (18 of 35) progressed to acute rejection. Infiltrates that progressed to rejection had more frequent glomerulitis (7 of 18 versus 3 of 47, P = 0.003) and Banff acute score indices (i+t+v+g) >2 (16 of 18 versus 29 of 47, P = 0.03). A majority (72%) of borderline infiltrates not given additional anti-rejection therapy did not progress to acute rejection over 40 d of follow-up, suggesting that conservative management of these lesions, at least in the short term, may be more appropriate than routine treatment as acute rejection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446950     DOI: 10.1681/ASN.V1081806

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  10 in total

1.  Intragraft levels of Foxp3 mRNA predict progression in renal transplants with borderline change.

Authors:  Hicham Mansour; Sébastien Homs; Dominique Desvaux; Cécile Badoual; Karine Dahan; Marie Matignon; Vincent Audard; Philippe Lang; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 10.121

Review 2.  Histopathological diagnosis of acute and chronic rejection in pediatric kidney transplantation.

Authors:  Verena Bröcker; Michael Mengel
Journal:  Pediatr Nephrol       Date:  2013-10-19       Impact factor: 3.714

3.  Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts.

Authors:  Oriol Bestard; Josep M Cruzado; Inés Rama; Joan Torras; Montse Gomà; Daniel Serón; Francesc Moreso; Salvador Gil-Vernet; Josep M Grinyó
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

4.  Molecular diagnostics identifies risks for graft dysfunction despite borderline histologic changes.

Authors:  Petra Hrubá; Irena Brabcová; Faikah Gueler; Zdeněk Krejčík; Viktor Stránecký; Eva Svobodová; Jana Malušková; Wilfried Gwinner; Eva Honsová; Alena Lodererová; Rainer Oberbauer; Roman Zachoval; Ondřej Viklický
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

5.  Urinary expression of kidney injury markers in renal transplant recipients.

Authors:  Cheuk-Chun Szeto; Bonnie Ching-Ha Kwan; Ka-Bik Lai; Fernand Mac-Moune Lai; Kai-Ming Chow; Gang Wang; Cathy Choi-Wan Luk; Philip Kam-Tao Li
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-29       Impact factor: 8.237

6.  The Outcome of Tapered Steroid Regimen When Used to Treat Acute Borderline Cellular Rejection After Kidney Transplant: A Single-Center Experience.

Authors:  Abdullah Jebrini; Ana Cecilia Farfan Ruiz; Meray Hosni; Tambi Jarmi
Journal:  J Clin Med Res       Date:  2022-09-29

Review 7.  Proposed Definitions of T Cell-Mediated Rejection and Tubulointerstitial Inflammation as Clinical Trial Endpoints in Kidney Transplantation.

Authors:  Daniel Seron; Marion Rabant; Jan Ulrich Becker; Candice Roufosse; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Fritz Diekmann; Denis Glotz; Luuk Hilbrands; Alexandre Loupy; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

8.  Chronic allograft injury by subclinical borderline change: evidence from serial protocol biopsies in kidney transplantation.

Authors:  Sang-Il Min; Young Suk Park; Sanghyun Ahn; Taejin Park; Dae Do Park; Suh Min Kim; Kyung Chul Moon; Seung-Kee Min; Yon Su Kim; Curie Ahn; Sang Joon Kim; Jongwon Ha
Journal:  J Korean Surg Soc       Date:  2012-11-27

9.  Delayed graft function is associated with an increased rate of renal allograft rejection: A retrospective single center analysis.

Authors:  Susanne Weber; Thomas Dienemann; Johannes Jacobi; Kai-Uwe Eckardt; Alexander Weidemann
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

10.  Practice Patterns in the Treatment and Monitoring of Acute T Cell-Mediated Kidney Graft Rejection in Canada.

Authors:  Julie Leblanc; Peter Subrt; Michèle Paré; David Hartell; Lynne Sénécal; Tom Blydt-Hansen; Héloïse Cardinal
Journal:  Can J Kidney Health Dis       Date:  2018-02-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.